Recent Updates
Recently added Catalysts
REPL Negative Sentiment Score: 20/100

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Replimune Group, Inc. for allegedly making misleading statements regarding the IGNYTE trial. The lawsuit, filed in the District Court of Massachusetts, encompasses all parties who acquired Replimune securities between November 22, 2024, and July 21, 2025. Investors have until September 22, 2025, to apply to be lead plaintiffs. The firm is soliciting further inquiries from affected investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Replimune Group, alleging misleading statements about the IGNYTE trial.
  • The lawsuit claims that defendants overstated the trial's prospects, resulting in the FDA deeming it inadequate.
  • Investors are encouraged to contact the law firm for potential legal actions due to losses suffered.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ:REPL) in the United States District Court District Of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Replimune securities between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”). Investors have until September 22, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased or otherwise acquired Replimune shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who can join the class action against Replimune?

Investors who purchased Replimune securities between November 22, 2024, and July 21, 2025.

What is the deadline to apply as lead plaintiff?

The deadline to apply as lead plaintiff is September 22, 2025.

Where was the class action lawsuit filed?

The lawsuit was filed in the United States District Court District Of Massachusetts.

What issues are claimed in the lawsuit?

The lawsuit claims misleading statements about the IGNYTE trial's success.

How can I contact Bragar Eagel & Squire for help?

You can call them at (212) 355-4648 or email investigations@bespc.com.

Last updated: Sep 11, 2025